Roux H. auteur aut IRD Touret Franck auteur aut IRD Rathelot P. auteur aut IRD Vanelle P. auteur aut IRD Roche M. auteur aut IRD text journalArticle eng text/pdf reformatted digital access Non-polio enteroviruses (NPEVs), namely coxsackieviruses (CV), echoviruses (E), enteroviruses (EV), and rhinoviruses (RV), are responsible for a wide variety of illnesses. Some infections can progress to life-threatening conditions in children or immunocompromised patients. To date, no treatments have been approved. Several molecules have been evaluated through clinical trials without success. To overcome these failures, the multi-target directed ligand (MTDL) strategy could be applied to tackle enterovirus infections. This work analyzes registered clinical trials involving antiviral drugs to highlight the best candidates and develops filters to apply to a selection for MTDL synthesis. We explicitly stated the methods used to answer the question: which solution can fight NPEVs effectively ? We note the originality and relevance of this proposal in relation to the state of the art in the enterovirus-inhibitors field. Several combinations are possible to broaden the antiviral spectrum and potency. We discuss data related to the virus and data related to each LEAD compound identified so far. Overall, this study proposes a perspective on different strategies to overcome issues identified in clinical trials and evaluate the "MTDL" potential to improve the efficacy of drugs, broaden the antiviral targets, possibly reduce the adverse effects, drug design costs and limit the selection of drug-resistant virus variants. specialized 052 050 17 9 1218 [41 ] 2024 1424-8247 https://www.documentation.ird.fr/hor/fdi:010093046 10.3390/ph17091218 1424-8247 [F B010093046] https://www.documentation.ird.fr/hor/fdi:010093046 https://horizon.documentation.ird.fr/exl-doc/pleins_textes/2025-02/010093046.pdf IRD - Base Horizon / Pleins textes 2025-02-07 2025-11-06 fdi:010093046 fre